Technology evaluation: Rexin-G, Epeius Biotechnologies.

Published

Journal Article (Review)

Rexin-G is a 'pathotropic', tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene, under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. The therapy is currently undergoing phase I/II clinical trials.

Full Text

Duke Authors

Cited Authors

  • Morse, M

Published Date

  • April 2005

Published In

Volume / Issue

  • 7 / 2

Start / End Page

  • 164 - 169

PubMed ID

  • 15844625

Pubmed Central ID

  • 15844625

International Standard Serial Number (ISSN)

  • 1464-8431

Language

  • eng

Conference Location

  • England